SOPHiA GENETICS
Oncology
-
On-demandPart 1: Homologous Recombination Deficiency (HRD) Detection
Originally presented at ESMO 2022
What’s New? CE-IVD Oncology Applications by SOPHiA GENETICS™
Alexander Kurze, PhD
Evaluation of a low-pass whole genome sequencing-based solution... -
On-demandPart 2: RNA fusion detection
Originally presented at ESMO 2022
Clinical validation of novel RNA fusion detection for NSCLC with SOPHiA DDM™ Dx RNAtarget Oncology Solution
Prof. Alexander Harlé, PhD
Enabling clinical workflows in Trusted Resea... -
On-demandPresented at The Cancer Genomics Consortium 2022 Annual Meeting
-
On-demandSOPHiA GENETICS has been working to deliver on the promise of integrated cancer care by bringing insights across multiple modalities to research, clinical and biopharma customers. View our presentation from the DASA Genomic Summit 2022 to discover...
-
Friday, July 22, 2022 · 2:00 PM CESTDeficiency in the homologous recombination repair system represent up to 50% of the ovarian, breast, prostate and pancreatic cancers. While Poly ADP-ribose polymerase inhibitors (PARPi) treatment revolutionized management of patients, inducing syn...
-
Thursday, June 30, 2022 · 4:00 PM CESTGene fusions are the latest type of biomarker to receive broad applicability in cancer management. More than 10,000 gene fusions have already been identified in human cancers and it is estimated that up to 80% of solid tumors could benefit from ge...
-
Tuesday, June 22, 2021 · 11:00 AM EDTHereditary cancer syndromes are a set of complex diseases, often presenting with diverse clinical phenotypes, involving multiple genes of interest with variable penetrance. Large scale genomic sequencing of multi-gene panels has become the standar...
BioPharma
-
On-demandThis panel discussion took place at BioData World Congress in Basel, Switzerland on 09 November.
Data integration and AI/ML are seemingly everywhere and are increasingly recognized as critical to accelerating the advancement of precision medicine... -
On-demandDelays in clinical trial patient enrollment are significant challenges for sponsors, especially for biomarker-targeted investigational therapies associated with rare genomic variants. Join us and discover the solutions offered by SOPHiA GENETICS, ...
On-demand
-
On-demandThis panel discussion took place at BioData World Congress in Basel, Switzerland on 09 November.
Data integration and AI/ML are seemingly everywhere and are increasingly recognized as critical to accelerating the advancement of precision medicine... -
On-demandPart 1: Homologous Recombination Deficiency (HRD) Detection
Originally presented at ESMO 2022
What’s New? CE-IVD Oncology Applications by SOPHiA GENETICS™
Alexander Kurze, PhD
Evaluation of a low-pass whole genome sequencing-based solution... -
On-demandPart 2: RNA fusion detection
Originally presented at ESMO 2022
Clinical validation of novel RNA fusion detection for NSCLC with SOPHiA DDM™ Dx RNAtarget Oncology Solution
Prof. Alexander Harlé, PhD
Enabling clinical workflows in Trusted Resea... -
On-demandPresented at The Cancer Genomics Consortium 2022 Annual Meeting
-
On-demandSOPHiA GENETICS has been working to deliver on the promise of integrated cancer care by bringing insights across multiple modalities to research, clinical and biopharma customers. View our presentation from the DASA Genomic Summit 2022 to discover...
-
On-demandPessoas reais, impactos reais. Assista a uma apresentação imperdível sobre como SOPHiA DDM tm otimiza a análise de exomas e painéis direcionados, inclusive no caso de doenças pediátricas raras. A apresentação será feita pela nossa cliente, Dra. Ol...
-
Friday, July 22, 2022 · 2:00 PM CESTDeficiency in the homologous recombination repair system represent up to 50% of the ovarian, breast, prostate and pancreatic cancers. While Poly ADP-ribose polymerase inhibitors (PARPi) treatment revolutionized management of patients, inducing syn...
-
On-demandOver the past decade, next-generation sequencing (NGS) has emerged as a comprehensive and cost-effective tool for the diagnosis and research of rare diseases. It is well known that mutations in nuclear DNA can cause a range of human diseases, with...
-
Thursday, June 30, 2022 · 4:00 PM CESTGene fusions are the latest type of biomarker to receive broad applicability in cancer management. More than 10,000 gene fusions have already been identified in human cancers and it is estimated that up to 80% of solid tumors could benefit from ge...
-
On-demandDelays in clinical trial patient enrollment are significant challenges for sponsors, especially for biomarker-targeted investigational therapies associated with rare genomic variants. Join us and discover the solutions offered by SOPHiA GENETICS, ...
-
On-demandA central focus of the BRIDGES project was to establish the validity and utility of personalized risk-based breast cancer prevention, and specifically of gene panel testing, within the clinical routine of high-risk Family Cancer Centers.
To this... -
On-demandCe webinar illustre l'apport complémentaire du séquençage moléculaire dans le cas d’un enfant de 15 ans, présentant une agénésie dentaire associée à des anomalies génitales.
Initialement un diagnostic d'oligodonties est suspecté. L'identification...
